Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 26  •  11:00AM ET
7.88
Dollar change
+2.81
Percentage change
55.45
%
Today, 5:30 AMEbola assay strategy announcement drives CODX premarket surge
Index
-
P/E
-
EPS (ttm)
-28.01
Insider Own
4.98%
Shs Outstand
3.60M
Perf Week
475.26%
Market Cap
28.38M
Forward P/E
-
EPS next Y
-
Insider Trans
0.00%
Shs Float
3.42M
Perf Month
371.92%
Enterprise Value
22.18M
PEG
-
EPS next Q
-
Inst Own
1.44%
Perf Quarter
237.66%
Income
-48.50M
P/S
55.66
EPS this Y
-
Inst Trans
-6.52%
Perf Half Y
-18.49%
Sales
0.51M
P/B
1.77
EPS next Y
-
ROA
-126.56%
Perf YTD
55.81%
Book/sh
4.45
P/C
3.45
EPS next 5Y
-
ROE
-151.66%
52W High
46.50 -83.05%
Perf Year
13.43%
Cash/sh
2.29
P/FCF
-
EPS past 3/5Y
-37.47% -
ROIC
-281.74%
52W Low
1.26 525.48%
Perf 3Y
-75.68%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-76.97% -64.54%
Gross Margin
-187.30%
Volatility
48.62% 23.31%
Perf 5Y
-96.79%
Dividend TTM
-
EV/Sales
43.50
EPS Y/Y TTM
18.03%
Oper. Margin
-6255.15%
ATR (14)
0.81
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
2.09
Sales Y/Y TTM
-9.46%
Profit Margin
-9438.49%
RSI (14)
88.14
Dividend Gr. 3/5Y
- -
Current Ratio
2.28
EPS Q/Q
42.48%
SMA20
242.31%
Beta
1.75
Payout
-
Debt/Eq
0.13
Sales Q/Q
190.30%
SMA50
294.64%
Rel Volume
12.86
Prev Close
5.07
Employees
115
LT Debt/Eq
0.07
SMA200
19.06%
Avg Volume
5.06M
Price
7.88
IPO
Jul 12, 2017
Option/Short
No / No
Trades
Volume
17,528,941
Change
55.45%
Today 09:00AM
May-19-26 10:54PM
10:34AM
May-15-26 08:30AM
01:02AM
04:01PM Loading…
May-14-26 04:01PM
May-11-26 05:43AM
May-08-26 09:00AM
Apr-16-26 09:00AM
Apr-14-26 09:00AM
Apr-09-26 09:00AM
Apr-02-26 09:00AM
Apr-01-26 08:30AM
Mar-31-26 11:02PM
04:01PM
08:00AM Loading…
Mar-25-26 08:00AM
Mar-20-26 03:30PM
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
ChairmanMr. Dwight H. Egan
PresidentMr. Richard David Abbott
CFO & Company SecretaryMr. Brian L. Brown CPA
Chief Operating OfficerMr. David Nielsen
Vice President of Finance & AccountingMr. Dan Bohrer CPA